Synapse - Myeloma

Results (1016)

Daratumumab, carfilzomib, lenalidomide, & dexamethasone for relapsed/refractory myeloma with salvage autologous hematopoietic cell transplant: Interim analysis of the multicenter 2nd chance protocol

Meeting Abstract

Shah, G.; Bal, S.; Rodriguez, C.; Chhabra, S.; Bayer, R.; Costa, L.; Lambird, J.; Ferrer, C.; Parascondola, A.; Marcello, L.; more...
Clinical Lymphoma, Myeloma and Leukemia (2021)

Fulltext@MSK | Save

Providing nutritional guidance for patients with plasma cell disorders - A missed opportunity for hematologists and oncologists?

Meeting Abstract

Sweeney, N.; Malik, M.; Jafri, M.; Derkach, A.; Chmielewski, C.; Adintori, P.; Mailankody, S.; Korde, N.; Tan, C.; Hassoun, H.; more...
Clinical Lymphoma, Myeloma and Leukemia (2021)

Fulltext@MSK | Save

Sustained minimal residual disease negativity in multiple myeloma is impacted positively by stool butyrate and healthier plant forward diets

Meeting Abstract

Shah, U.; Derkach, A.; Adintori, P.; Cross, J.; Maclachlan, K.; Mailankody, S.; Korde, N.; Hultcrantz, M.; Hassoun, H.; Tan, C.; more...
Clinical Lymphoma, Myeloma and Leukemia (2021)

Fulltext@MSK | Save

MagnetisMM-1 study of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA) targeted CD3-engaging bispecific molecule, for patients (pts) with relapsed or refractory multiple myeloma (MM)

Meeting Abstract

Dholaria, B.; Bahlis, N.; Raje, N.; Costello, C.; Solh, M.; Levy, M.; Tomasson, M.; Dube, H.; Damore, M.; Lon, H. K.; more...
Clinical Lymphoma, Myeloma and Leukemia (2021)

Fulltext@MSK | Save

Carfilzomib, lenalidomide, and dexamethasone followed by lenalidomide maintenance for prevention of symptomatic multiple myeloma in patients with high-risk smoldering myeloma: A phase 2 nonrandomized controlled trial

Journal Article

Kazandjian, D.; Hill, E.; Dew, A.; Morrison, C.; Roswarski, J.; Korde, N.; Emanuel, M.; Petrosyan, A.; Bhutani, M.; Calvo, K. R.; more...
JAMA Oncology (2021)

Fulltext@MSK | Save

Disease- and therapy-specific impact on humoral immune responses to COVID-19 vaccination in hematologic malignancies

Journal Article

Chung, D. J.; Shah, G. L.; Devlin, S. M.; Ramanathan, L. V.; Doddi, S.; Pessin, M. S.; Hoover, E.; Marcello, L. T.; Young, J. C.; Boutemine, S. R.; more...
Blood Cancer Discovery (2021)

Fulltext@MSK | Save

HORIZON (OP-106): Melflufen plus dexamethasone in 55 patients with relapsed/refractory multiple myeloma with extramedullary disease-subgroup analysis

Meeting Abstract

Richardson, P.; Mateos, M. V.; Oriol, A.; Larocca, A.; Cavo, M.; Rodriguez-Otero, P.; Leleu, X.; Norkin, M.; Nadeem, O.; Hiemenz, J.; more...
American Journal of Hematology (2021)

Fulltext@MSK | Save

Melflufen plus dexamethasone in patients with relapsed/refractory multiple myeloma exposed and/or refractory to prior alkylators - A pooled analysis of the O-12-M1 and HORIZON studies

Meeting Abstract

Rodriguez-Otero, P.; Mateos, M. V.; Oriol, A.; Larocca, A.; Blade, J.; Cavo, M.; Leleu, X.; Nadeem, O.; Hiemenz, J.; Hassoun, H.; more...
American Journal of Hematology (2021)

Fulltext@MSK | Save

MagnetisMM-1: A study of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-targeted, CD3-engaging bispecific antibody, for patients with relapsed or refractory multiple myeloma (MM)

Meeting Abstract

Levy, M.; Bahlis, N.; Raje, N.; Costello, C.; Dholaria, B.; Solh, M.; Tomasson, M.; Dube, H.; Damore, M.; Lon, H. K.; more...
Clinical Lymphoma, Myeloma and Leukemia (2021)

Fulltext@MSK | Save

Belantamab mafodotin (belamaf; GSK2857916) US expanded access program (EAP) for heavily pre-treated patients with relapsed/refractory multiple myeloma (RRMM): Baseline characteristics

Meeting Abstract

Hultcrantz, M.; Anderson, L. D. Jr; Anwer, F.; Gasparetto, C.; Kocoglu, M. H.; Lichtman, E. I.; Mo, C.; Niesvizky, R.; Lewis, E.; Li, H.; more...
Clinical Lymphoma, Myeloma and Leukemia (2021)

Fulltext@MSK | Save